相关实验视频
Updated: Jun 22, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.9K
分子亚型和TP53在扩散大B细胞淋巴瘤和里希特综合征中的作用
Ivan Negara1,2, Ciprian Tomuleasa3, Sanda Buruiana2
1Molecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, 34149 Trieste, Italy.
Cancers
|June 27, 2024
概括
TP53基因突变是扩散型大B细胞淋巴瘤 (DLBCL) 的关键预后指标. 确定TP53状态为DLBCL患者的风险分层和潜在治疗指导提供了实用方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种常见且异质的淋巴细胞癌.
- 新的遗传分类存在,但对于常规临床使用而言是复杂的.
- 在DLBCL中,TP53基因突变很常见 (20-30%) 并具有临床意义.
研究的目的:
- 评估DLBCL中TP53基因状态的预后意义.
- 探索TP53突变状态对于风险分层的潜力.
- 突出在DLBCL中需要实用的预后模型.
主要方法:
- 在DLBCL患者队列中分析TP53基因状态.
- TP53突变与临床结果和治疗反应的相关性.
- 将TP53状态与现有的DLBCL分类系统进行比较.
主要成果:
- 在TP53遗传病变中,DLBCL亚型具有类似于里希特综合征的丰富性.
- 包括里希特综合征在内的TP53突变DLBCL患者的预后不佳.
- 突变TP53的DLBCL对标准化疗免疫疗法的反应较差.
结论:
- TP53突变状态是DLBCL的关键预后因素.
- TP53状态可以帮助对DLBCL患者进行风险分层.
- 针对TP53的改变可能会改善DLBCL治疗策略.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K

